Rabbit anti Human Interleukin-10 antibody recognizes human IL-10 (Interleukin-10), an 18.5kDa immunosuppressive cytokine originally known as cytokine synthesis inhibiting factor (CSIF), which specifically regulates immune-mediated inflammation and shares high sequence homology with murine IL-10 and the viral protein BCRF1.
IL-10, produced by macrophages, mast cells, T cells, activated B cells and keratinocytes, inhibits the secretion of a variety of pro-inflammatory cytokines including TNFalpha, IL-1, IL-2, IL-3 and IL-8 and is chemotactic for CD8+ T cells. The suppressive ability of IL-10 has become a focus area for the treatment of Crohn’s disease, but with conflicting results.
- Target Species
- Product Form
- Purified IgG - lyophilised
- Reconstitute with 0.1ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
For long term storage the addition of 0.09% sodium azide is recommended. N.B. For functional studies do not add sodium azide.
- Antiserum Preparation
- Antisera to human IL-10 were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG prepared by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- None present
- Recombinant human IL-10
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml after reconstitution
- Prior to reconstitution store at -20oC.
After reconstitution store at -20oC.
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 6 months from date of reconstitution
- Entrez Gene
- GO Terms
negative regulation of cytokine secretion involved in immune response
positive regulation of B cell apoptosis
interleukin-10 receptor binding
cytoplasmic sequestering of NF-kappaB
growth factor activity
B cell differentiation
negative regulation of B cell proliferation
negative regulation of interleukin-6 production
receptor biosynthetic process
type 2 immune response
B cell proliferation
negative regulation of T cell proliferation
positive regulation of gene-specific transcription
regulation of isotype switching
negative regulation of MHC class II biosynthetic process
negative regulation of interferon-alpha biosynthetic process
positive regulation of cytokine secretion
negative regulation of membrane protein ectodomain proteolysis
positive regulation of transcription factor activity
response to glucocorticoid stimulus
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of IL-10 antibody
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- This purified human IL-10antibody may be used in an indirect ELISA with recombinant human IL-10 (PHP047A) as the standard.
- Western Blotting
- This antibody may be used in Western Blotting under either reducing or non-reducing conditions with recombinant human IL-10 (PHP047A) as the positive control.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Useful Reagents Available
Positive Isotype Controls Available
Product Specific References
References for IL-10 antibody
Gesser, B. et al. (1997) Identification of functional domains on human interleukin 10.
Proc Natl Acad Sci U S A. 94 (26): 14620-5.
NaqviS, E.H. et al. (2017) A Prospective Study of Altered Inflammatory Response and Its Clinical Outcome following Laparoscopic and Open Cholecystectomy.
Iran J Med Sci. 42 (4): 347-53.
Tilg, H. et al. (2002) Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.
Gut. 50 (2): 191-5.